@article{Jeffreys_L-2022_58804,
title = {Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2},
author = {Jeffreys, L. and Pennington, S. and Duggan, J. and Caygill, C. and Lopeman, R. and Breen, A. and Jinks, J. and Ardrey, A. and Donnellan, S. and Patterson, E. and Hughes, G. and Hong, D. and O'Neill, P. and Aljayyoussi, G. and Owen, A. and Ward, S. and Biagini, G.},
month = {jan},
year = {2022},
abstract = {A key element for the prevention and management of COVID-19 is the development of effective therapeutics. Drug combination strategies of repurposed drugs offer several advantages over monotherapies, including the potential to achieve greater efficacy, the potential to increase the therapeutic index of drugs and the potential to reduce the emergence of drug resistance. Here, we report on the in vitro synergistic interaction between two FDA approved drugs, remdesivir and ivermectin resulting in enhanced antiviral activity against SARS-CoV-2. Whilst the in vitro synergistic activity reported here does not support the clinical application of this combination treatment strategy, due to insufficient exposure of ivermectin in vivo, the data do warrant further investigation. Efforts to define the mechanisms underpinning the observed synergistic action, could lead to the development of novel therapeutic treatment strategies.},
volume = {59},
issue = {3},
journal = {International Journal of Antimicrobial Agents},
publisher = {Elsevier},
url = {https://doi.org/10.1016/j.ijantimicag.2022.106542},
}
